Dr. Chakravarthy from Belfast, UK discusses a secondary analysis of the IVAN Trial to compare effects of intravitreal anti-VEGF therapy on serum VEGF levels with possible trends in system adverse events in the context of wet AMD. Full reference: Chris A.Rogers, Lauren J.Scott, Barnaby C.Reeves, Susan Downes, Andrew J.Lotery, Andrew D.Dick, Usha Chakravarthy for IVAN trial investigators, Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events, Ophthalmology Retina, Feb. 2018 http://dx.doi.org/10.1016/j.oret.2017.05.015